Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab maintenance versus no further treatment in relapsed CLL after response to induction
2009-012518-39Phase 3Terminated
- Sponsor
- GSK
- Start
- Dec 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ofatumumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by GSK. Primary endpoint: Progression-free survival. Started Dec 2009; status: terminated.
02
Drugs
ofatumumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2009-012518-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012518-39.